专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20140134243A1 Compositions for the Treatment of CNS-Related Conditions 审中-公开
标题翻译： CNS相关条件治疗组合物
公开(公告)号：US20140134243A1
公开(公告)日：2014-05-15
申请号：US13863140
申请日：2013-04-15
申请人： Adamas Pharmaceuticals, Inc.
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K31/445 , A61K9/48 , A61K31/13
CPC分类号： A61K9/2054 , A61K9/0053 , A61K9/1635 , A61K9/1652 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2059 , A61K9/2813 , A61K9/282 , A61K9/48 , A61K9/4808 , A61K9/7061 , A61K31/13 , A61K31/445 , A61K45/06 , A61K2300/00 , Y02A50/401
摘要： The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.
摘要翻译：本发明提供了用金刚胺和多奈哌齐来处理CNS相关病症的方法，其中金刚烷胺为延长释放形式，其中延长释放金刚烷胺制剂提供作为时间（dC / dT）的函数的血浆浓度变化，其为少于dC / dT的相同量的立即释放形式的金刚烷胺的40％。

62. 发明申请

US20130165527A1 Method for Administering an NMDA Receptor Antagonist to a Subject 有权
标题翻译：管理受试者的NMDA受体拮抗剂的方法
公开(公告)号：US20130165527A1
公开(公告)日：2013-06-27
申请号：US13751876
申请日：2013-01-28
申请人： ADAMAS PHARMACEUTICALS, INC.
发明人： Gregory T. Went , Timothy J. Fultz , Laurence R. Meyerson
IPC分类号： A61K31/13
CPC分类号： A61K31/13 , A61K9/4891 , Y10S514/964
摘要： Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
摘要翻译：提供了向受试者施用美金刚的组合物和方法。特别地，提供了一次每日口服给药的单位剂型的固体药物组合物。组合物包含22.5mg至33.75mg美金刚或其药学上可接受的盐的延长释放制剂，其中向人受试者施用该剂量的组合物提供了以美金刚浓度变化为特征的平均血浆美金刚浓度分布时间的函数（dC / dT）小于在美金刚给药后0小时至6小时之间的时间段内由相同量的美金刚立即释放形式提供的dC / dT的50％，其中在单次剂量人体PK研究中测量dC / dT。提供了使用该组合物治疗痴呆，特别是阿尔茨海默氏病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式